Comparing Biotricity (NASDAQ:BTCY) & Pulmonx (NASDAQ:LUNG)

Pulmonx (NASDAQ:LUNG) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Pulmonx and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	-72.01%	-53.88%	-33.47%
Biotricity	-97.05%	N/A	-221.26%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Pulmonx and Biotricity, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	2	4	0	2.67
Biotricity	0	1	0	0	2.00

Pulmonx presently has a consensus target price of $12.75, indicating a potential upside of 86.40%. Given Pulmonx’s stronger consensus rating and higher probable upside, equities analysts plainly believe Pulmonx is more favorable than Biotricity.

Institutional and Insider Ownership

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by company insiders. Comparatively, 10.1% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Pulmonx and Biotricity”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$79.30 million	3.41	-$60.84 million	($1.47)	-4.65
Biotricity	$12.06 million	0.71	-$14.09 million	($1.37)	-0.26

Biotricity has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Pulmonx has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.

Summary

Pulmonx beats Biotricity on 8 of the 14 factors compared between the two stocks.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.